Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Short term Debt: 2022

  • RedHill Biopharma's Short term Debt was N/A to $115.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $115.2 million, marking a year-over-year change of. This contributed to the annual value of $115.2 million for FY2022, which is N/A change from last year.
  • Latest data reveals that RedHill Biopharma reported Short term Debt of $115.2 million as of Q4 2022.
  • RedHill Biopharma's 5-year Short term Debt high stood at $115.2 million for Q4 2022, and its period low was $115.2 million during Q4 2022.
  • For the 1-year period, RedHill Biopharma's Short term Debt averaged around $115.2 million, with its median value being $115.2 million (2022).